IDH1 and acute myeloid leukemia: These original discoveries led to a surge of sequencing studies reporting mutations in the IDH1 and IDH2 isozymes in AML and other cancers, and soon after, small molecule inhibitors targeting mutated IDH1/2 (mIDH) entered the clinic, which have produced exciting results [17,18,19,20,21,22,23,24,25].